61 results about "Keratoconus" patented technology

The disclosure concerns altering the mechanical and / or chemical property of a body tissue, particularly an ocular tissue. In specific cases, it concerns altering or stabilizing the shape of the cornea, such as in a subject suffering or at risk for ectasia or keratoconus. In other specific cases, it concerns strengthening the sclera in a subject suffering or at risk for myopia. The invention employs light irradiation of a photoactivatable compound, such as one that applies crosslinking to the tissue, for example.

Disclosed are compounds and related methods useful for cross-linking collagen and stabilizing collagenous tissues using formaldehyde-donating compounds or nitrogen oxide-containing compounds such as β-Nitro Alcohols. Also disclosed are compounds and related methods for modulating the rate or degree of collagen cross-linking using nitrogen oxide-containing compounds such as β-Nitro Alcohols. The formaldehyde-donating, nitrogen oxide-containing and / or β-Nitro Alcohol compounds disclosed are capable of stabilizing collagenous tissues such as the corneal and scleral tissues and are useful in the treatment or prevention of diseases such as alterations in corneal curvature, keratoconus, keratectasia, progressive myopia and glaucoma.

Trans-epithelial osmotic collyrium for the treatment of keratoconus by corneal cross-linking with UV rays, of the type consisting of a riboflavin-based solution and an absorption enhancement adjuvant consisting of benzalkonium chloryde (BAC). The solution has a hypoosmolarity degree ranging between −70% and −30% over an isotonic solution and contains a BAC concentration accordingly ranging between 0.005% and 0.035%.

A method for stabilizing collagenous eye tissues by nitrite and nitroalcohol treatment. The topical stiffening agent contains sodium nitrite or a nitroalcohol in a buffered balanced salt solution and can be applied to the surface of the eye on a daily basis for a prolonged period. Application of the solution results in progressive stabilization of the corneal and scleral tissues through non-enzymatic cross-linking of collagen fibers. The compounds can penetrate into the corneal stroma without the need to remove the corneal epithelium. In addition, ultraviolet light is not needed to activate the cross-linking process. The resulting stabilization of corneal and scleral tissues can prevent future alterations in corneal curvature and has utility in diseases such as keratoconus, keratectasia, progressive myopia, and glaucoma.

The present invention is directed to a non-deforming contact lens for keratoconus patients comprising a central zone having a displaced central zone. In particular, the central zone is displaced from the geometric center of the lens. The shape of the central zone is egg or spoon-shaped and is rotationally asymmetrical with one semi-meridian that is shorter than a corresponding semi-meridian. An intermediate transition zone is formed integral with the periphery of the central zone, and a peripheral zone is formed integral with the periphery of the intermediate transition zone, forming a round contact lens.

The invention discloses a keratoconus recognition method and system based on multi-dimensional feature self-adaptive fusion. The method comprises the following steps: (1) obtaining original corneal topographic map data of a plurality of independent samples by using a Pentacam anterior segment imaging system; (2) carrying out comprehensive judgment and labeling on the condition of the conic corneaon the five dimensions of each independent sample; (3) counting normal size, mean value, variance and extreme value information of original corneal topographic map data of five dimensions; (4) dividing a training set and a verification set; (5) processing topographic map data in the training set and the verification set; (6) constructing and training a residual convolutional neural network with five-dimensional feature adaptive fusion; (7) utilizing a Grad-CAM visualization mode to obtain average visualization information of the three types of test samples; and (8) performing prediction by using the trained model, and performing back propagation on the maximum prediction score to obtain a visual effect picture. According to the invention, the problem of poor recognition effect of the coniccornea in practical application can be solved.

A contact lens for cornea-correction crosslinking made of an ultraviolet transmitting material includes, on a cornea contact side, a pressing region projecting in a convex curved-surface shape at a position corresponding to the center of a corneal dome to be pressed and a relief region constituted by an annular concave portion in a circular arc shape, encircling the outer periphery of the pressing region. The contact lens corrects at least naked eye vision or keratoconus cornea by pressing both regions to the cornea and changing its shape. The contact lens includes a reservoir portion outside the pressing region in a lens thickness direction for a riboflavin solution, a communication hole communicating the reservoir portion inside with the pressing region, and an operation-side electrode having the same polarity as that of the riboflavin solution. The mounted contact lens allows riboflavin solution infiltration into corneal tissue by iontophoresis and ultra-violet ray irradiation.

The present invention relates generally to a medicinal solution, and more particularly to a medicinal solution which is to be continuously or pulse-delivered for the purpose of treating various ocular diseases, conditions, or maladies, such as keratoconus, infectious keratitis, severe inflammatory conditions, and ocular surface neoplasia. In particular, the medicinal solution comprises the combination of a medication for treating one of the aforenoted or similar diseases, conditions, or maladies, and an anesthetic for rendering the patient comfortable during the treatment procedure.

The disclosure relates to a platform of using zebrafish in screening candidates for treating and / or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and / or the regulation of eyeball size. These drugs are potential candidates for treating myopia and / or keratoconus disease.

An ocular system for detecting ocular abnormalities and conditions creates photorefractive digital images of a patient's retinal reflex. The system includes a computer control system, a two-dimensional array of infrared irradiation sources and a digital infrared image sensor. The amount of light provided by the array of irradiation sources is adjusted by the computer so that ocular signals from the image sensor are within a targeted range. Enhanced, adaptive, photorefraction is used to observe and measure the optical effects of Keratoconus. Multiple near-infrared (NIR) sources are preferably used with the photorefractive configuration to quantitatively characterize the aberrations of the eye. The infrared light is invisible to a patient and makes the procedure more comfortable than current ocular examinations.

Methods of stabilizing collagen fibrils in a cornea are disclosed. The stabilization may be effected by treating the cornea with a protein that crosslinks collagen fibrils, such as decorin. The stablization methods include treatment of corneas before, during, or after a surgical procedure, treatment of keratectasia, and treatment of keratoconus.

The present invention relates to novel pharmaceutical formulations. More specifically, the present invention relates to novel pharmaceutical formulations that are suitable for intraocular administration. The present invention also relates to the use of these formulations for the treatment of collagenic eye disorder such as, for example, the treatment of keratoconus.

Ocular iontophoresis device and method for delivering any ionized drug solution to the cornea includes: a reservoir containing a solution suitable to be positioned on the eye; an active electrode disposed in or on the reservoir; and a passive electrode suitable to be placed on the skin of the subject, elsewhere on the body; elements for irradiating the cornea surface with suitable light for obtaining corneal cross-linking after the drug delivery; wherein the reservoir and the active electrode are transparent to UV light and / or visible light and / or IR light. The method includes: positioning the iontophoretic device on the eye to be treated; driving the solution by a cathodic current applied for 0.5 to 5 min, at an intensity not higher than 2 mA; and thereafter irradiating, with UV light for 5 to 30 min at a power of 3 to 30 mW / cm2; thereby obtaining the corneal cross-linking of the solution.

A kit for determining a hypothetical cornea for use with post-LASIK and post myopia Ortho-K amendment. The kit has a reference table for determining conformation data by using at least one of following data: pre-treatment KM readings, post-treatment KM readings, power reduced from before- to after-treatment, and post-treatment cornea optical zone. The kit further comprises a plurality of conformed lenses based on the conformation data in predetermined increments from the reference table. The pre-treatment KM readings comprise pre-operative or pre-ortho-K readings. The post-treatment KM readings comprise post-operative or post ortho-K readings. The post-treatment cornea optical zone comprises post-operative or post-ortho-K cornea optical zone. Also, a method of determining a hypothetical cornea for use with post-LASIK and post myopia Ortho-K amendment is disclosed. The method has inputting pre-treatment KM readings, inputting post-treatment KM readings, inputting power reduced from before- to after treatment, inputting post-treatment cornea optical zone, calculating conformation data, which is adapted to be used to generate specification for conformed lenses. Another kit for determining a hypothetical cornea for use with Keratoconus and post-hyperopia Ortho-K amendment can be constructed using at least one of following data: pre-altered KM readings, post-altered KM readings, pre-altered refraction error, and post altered specifications. The kit further comprises a plurality of conformed lenses based on the conformation data in predetermined increments from the reference table. The pre-altered KM readings comprise pre-keratoconus or pre-hyperopia ortho-K readings. The pre-altered refraction errors comprise refraction errors from a set of normal corneas. The post-altered specifications comprise cone widths of Keratoconus or steepened cornea zone of hyperopic Ortho-K and also magnitude of off centering of the cone apex.

This invention relates to the use of a heparanase inhibitor for treating, or inhibiting the progression or development of, an ocular inflammatory disorder, such as age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, retinal 5 vein occlusion, retinoblastoma, uveitis, macular edema, dry eye, ocular inflammation associated with an infection or keratoconus.